Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -19.06
- Piotroski Score 3.00
- Grade Neutral
- Symbol (VRCA)
- Company Verrica Pharmaceuticals Inc.
- Price $0.89
- Changes Percentage (6.59%)
- Change $0.05
- Day Low $0.81
- Day High $0.89
- Year High $11.41
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/27/2025
- Fiscal Year End N/A
- Average Stock Price Target $12.00
- High Stock Price Target $14.00
- Low Stock Price Target $10.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.77
- Trailing P/E Ratio -4.62
- Forward P/E Ratio -4.62
- P/E Growth -4.62
- Net Income $-66,995,000
Income Statement
Quarterly
Annual
Latest News of VRCA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Verrica Pharmaceuticals Inc. (VRCA): Worst 52-Week Low Stock to Buy Now
The recent interest rate cut by the U.S. Federal Reserve has boosted investor sentiment and market outlook. With stocks rallying, the focus shifts to stocks at 52-week lows, presenting potential buyin...
By Yahoo! Finance | 1 month ago -
When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Turn A Profit?
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, is expected to break even by 2026. Analysts project a profit of US$2.0m after a final loss in 2025....
By Yahoo! Finance | 2 months ago -
Recent 12% pullback would hurt Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders
Individual insiders hold the largest stake in Verrica Pharmaceuticals, followed by institutional investors and hedge funds. Top shareholders have the power to influence company decisions. Insider owne...
By Yahoo! Finance | 4 months ago
